06:12 AM EDT, 07/30/2026 (MT Newswires) -- United Securities LLC revised its price target for Jamjoom Pharmaceuticals Factory (SASE:4015) as analysts noted the company's second-quarter performance. "Jamjoom Pharma delivered a resilient performance despite a challenging operating environment. We remain constructive on the company, supported by its improving operational efficiency, scalable manufacturing platform, and growth opportunities from new strategic partnerships. While the near-term outlook may remain constrained by weak market conditions, we continue to view the long-term growth trajectory positively," analysts said in a Wednesday note. For the second quarter, the company posted a 4.2% annual increase in net profit to 137.6 million Saudi riyals, which missed United Securities' estimate by 5.5%. Revenue rose 12.4% year over year to 445 million riyals, "broadly" aligned with the research firm's forecast. "Management has maintained its full-year guidance despite the seasonally weaker second half, reflecting confidence in the underlying business. Accordingly, we retain our 2026e full year revenue estimates but modestly reduce our net profit forecast to SAR 500mn to reflect continued margin pressure. We also lower our target price to SAR 149.40 per share and maintain our Hold rating on the stock," the research firm wrote.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.